The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

Immune checkpoint inhibitors, namely anti-CTLA-4, anti-PD-1 and anti-PD-L1 monoclonal
antibodies, have emerged in the last decade as a novel form of cancer treatment, promoting …

Context Thyroid dysfunction occurs commonly following immune checkpoint inhibition. The
etiology of thyroid immune-related adverse events (irAEs) remains unclear and clinical …

Immune checkpoints are small molecules present on the cell surface of T-lymphocytes. They
maintain self-tolerance and regulate the amplitude and duration of T-cell responses …

Context The significance of thyroid peroxidase (TPOAb) and thyroglobulin antibody (TgAb)
in the pathogenesis of thyroid immune-related adverse events (irAEs) is unknown. Objective …

Checkpoint inhibitors are now widely used in the management of many cancers. Endocrine
toxicity are amongst the most common side effects. These endocrinopathies differ form from …

Abstract Context Positive antithyroglobulin (TgAb) and/or antithyroid peroxidase antibodies
(TPOAb) at baseline indicate a high risk of thyroid immune-related adverse events (irAEs) …

Simple Summary To capitalize on the revolutionary anticancer efficacy of immune
checkpoint inhibitors (ICPi) in an expanding list of tumors, including hematological …

Checkpoint inhibitors are monoclonal antibodies that elicit an anti-tumor response by
stimulating immune system. Their use has improved the treatment of different types of cancer …

Background Thyroid dysfunction is a common adverse event after immune checkpoint
inhibitor (ICI) therapy. The clinical manifestations of thyroid immune-related adverse events …